NASDAQ: OVIDOvid Therapeutics Inc Stock
$3.21+0.10 (+3.22%)
Updated Apr 18, 2024
OVID Price
$3.21
Fair Value Price
-$0.29
Market Cap
$226.98M
52 Week Low
$2.57
52 Week High
$4.14
P/E
-4.34x
P/B
2.59x
P/S
580.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$391.70k
Earnings
-$52.34M
Gross Margin
100%
Operating Margin
-13,362.17%
Profit Margin
-13,362.2%
Debt to Equity
0.64
Operating Cash Flow
-$46M
Beta
0.84
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OVID Overview
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OVID scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OVID ($3.21) is overvalued by 1,203.24% relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OVID ($3.21) is not significantly undervalued (1,203.24%) relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OVID is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OVID due diligence checks available for Premium users.
Be the first to know about important OVID news, forecast changes, insider trades & much more!
OVID News
Valuation
OVID fair value
Fair Value of OVID stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
-$0.29
Undervalued by
1,203.24%
OVID ($3.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OVID ($3.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OVID is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OVID price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.34x
Industry
15.68x
Market
41.33x
OVID price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.59x
Industry
5.76x
OVID is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OVID's financial health
Profit margin
Revenue
$141.6k
Net Income
-$15.3M
Profit Margin
-10,823.5%
OVID's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OVID's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$144.0M
Liabilities
$56.2M
Debt to equity
0.64
OVID's short-term assets ($109.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OVID's short-term assets ($109.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OVID's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OVID's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.9M
Investing
-$48.5M
Financing
$30.0M
OVID's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OVID vs Biotech Stocks
Ovid Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.